Matrix abnormalities in pulmonary fibrosis
- PMID: 29950306
- PMCID: PMC9489108
- DOI: 10.1183/16000617.0033-2018
Matrix abnormalities in pulmonary fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive disease, marked by excessive scarring, which leads to increased tissue stiffness, loss in lung function and ultimately death. IPF is characterised by progressive fibroblast and myofibroblast proliferation, and extensive deposition of extracellular matrix (ECM). Myofibroblasts play a key role in ECM deposition. Transforming growth factor (TGF)-β1 is a major growth factor involved in myofibroblast differentiation, and the creation of a profibrotic microenvironment. There is a strong link between increased ECM stiffness and profibrotic changes in cell phenotype and differentiation. The activation of TGF-β1 in response to mechanical stress from a stiff ECM explains some of the influence of the tissue microenvironment on cell phenotype and function. Understanding the close relationship between cells and their surrounding microenvironment will ultimately facilitate better management strategies for IPF.
Copyright ©ERS 2018.
Conflict of interest statement
Conflict of interest: M. Kolb reports a research grant from Intermune/Roche Canada, during the conduct of the study. He also reports grants and personal fees from Roche, Boehringer Ingelheim and GSK, personal fees from Gilead, Prometic and Genoa, and grants from Actelion, Respivert, Alkermes and Pharmaxis, outside the submitted work. Conflict of interest: C. Upagupta reports grants from the Canadian Institute for Health Research, during the conduct of the study. Conflict of interest: C. Shimbori reports grants from the Canadian Institute for Health Research, during the conduct of the study.
Figures

Comment in
- doi: 10.1183/16000617.0040-2018
Similar articles
-
Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production.J Cell Physiol. 2021 Oct;236(10):6836-6851. doi: 10.1002/jcp.30380. Epub 2021 Apr 14. J Cell Physiol. 2021. PMID: 33855709 Free PMC article.
-
Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways.Toxicol Lett. 2020 Mar 15;321:103-113. doi: 10.1016/j.toxlet.2019.11.003. Epub 2019 Nov 6. Toxicol Lett. 2020. PMID: 31706003
-
Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung.JCI Insight. 2017 Dec 21;2(24):e96352. doi: 10.1172/jci.insight.96352. JCI Insight. 2017. PMID: 29263297 Free PMC article.
-
Lung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis.Ann Am Thorac Soc. 2016 Dec;13 Suppl 5:S417-S421. doi: 10.1513/AnnalsATS.201605-341AW. Ann Am Thorac Soc. 2016. PMID: 28005427 Review.
-
The Role of Interaction between Mitochondria and the Extracellular Matrix in the Development of Idiopathic Pulmonary Fibrosis.Oxid Med Cell Longev. 2021 Oct 18;2021:9932442. doi: 10.1155/2021/9932442. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34707784 Free PMC article. Review.
Cited by
-
Integrated PPI- and WGCNA-retrieval of hub gene signatures for soft substrates inhibition of human fibroblasts proliferation and differentiation.Aging (Albany NY). 2022 Sep 2;14(17):6957-6974. doi: 10.18632/aging.204258. Epub 2022 Sep 2. Aging (Albany NY). 2022. PMID: 36057261 Free PMC article.
-
Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis.Am J Respir Cell Mol Biol. 2021 Oct;65(4):347-365. doi: 10.1165/rcmb.2020-0476TR. Am J Respir Cell Mol Biol. 2021. PMID: 34129811 Free PMC article. Review.
-
Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation.Molecules. 2023 Jan 11;28(2):753. doi: 10.3390/molecules28020753. Molecules. 2023. PMID: 36677811 Free PMC article.
-
Autonomously Propelled Colloids for Penetration and Payload Delivery in Complex Extracellular Matrices.Micromachines (Basel). 2021 Oct 6;12(10):1216. doi: 10.3390/mi12101216. Micromachines (Basel). 2021. PMID: 34683267 Free PMC article. Review.
-
Drugs targeting CTGF in the treatment of pulmonary fibrosis.J Cell Mol Med. 2024 May;28(10):e18448. doi: 10.1111/jcmm.18448. J Cell Mol Med. 2024. PMID: 38774993 Free PMC article. Review.
References
-
- Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med 2014; 189: 1161–1172. - PubMed
-
- Vancheri C, Failla M, Crimi N, et al. . Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496–504. - PubMed
-
- Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440. - PubMed
-
- Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015; 191: 252–254. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources